HALOZYME THERAPEUTICS, INC. Lessee, Operating Lease, Liability, to be Paid, after Year Five
HALOZYME THERAPEUTICS, INC. (HALO) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $747.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-02-17
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $747.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $6.08M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $11.69M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $17.13M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $747.00K 10-K · filed 2026-02-17 |
| 2024-12-31 | $6.08M 10-K · filed 2025-02-18 |
| 2023-12-31 | $11.69M 10-K · filed 2024-02-20 |
| 2022-12-31 | $17.13M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |